BLUE News and Press, bluebird bio Inc. From 01/05/22

bluebird bio, Inc . (Nasdaq: BLUE) today announced that members of the management team will present at the virtual 40 th Annual J.P. Morgan Healthcare Conference, Wednesday, January 12, at 3:45 p.m. ET. To access the live webcast of bluebird bio’s presentation, pl...

BioLife Solution is enjoying robust growth years over years. The company is riding the strong industry tailwinds as a logistics service provider for cell-based therapeutic innovators. Due to strategic acquisitions, BioLife is generating triple-digit top-line growth. For furt...

Shares of Bluebird Bio (NASDAQ: BLUE) were plunging 22.3% as of 10:41 a.m. ET on Monday. The big drop came after the company announced that the Food and Drug Administration (FDA) placed its clinical testing of lovo-cel in treating sickle cell disease on partial clinical hold. This p...

The FDA has placed a partial clinical hold on bluebird bio's (NASDAQ:BLUE) lovotibeglogene autotemcel (lovo-cel) gene therapy for sickle cell disease those under 18. Shares are down 20% in premarket trading. The hold relates to an ongoing investigation into an adolescent patient wit...

bluebird bio, Inc . (NASDAQ: BLUE) today announced that the FDA has placed its clinical program for lovotibeglogene autotemcel (lovo-cel) gene therapy for sickle cell disease (SCD) on partial clinical hold for patients under the age of 18. The partial, temporary suspension relates t...

bluebird bio (NASDAQ:BLUE) announces that the FDA has accepted for priority review the Biologics License Application (BLA) for elivaldogene autotemcel (eli-cel, Lenti-D), a gene therapy for cerebral adrenoleukodystrophy (CALD) in patients less than 18 years of age. The agency set a PDUFA goal...

BEAM's novel CRISPR technology gives it a niche in a crowded and volatile market alongside other CRISPR companies trading at high valuations. While the 'standard' CRISPR-cas9 approach cuts double-stranded DNA and to insert genetic sequences, base editing erases a point mutation and re...

If approved, eli-cel will be the first and only gene therapy for the treatment of CALD, a rare neurodegenerative disease primarily affecting young children that can lead to progressive, irreversible loss of neurologic function and death FDA set PDUFA date of June 17, 2022 ...

Apple (NASDAQ:AAPL) was in focus during Monday's pre-market action. Shares of the iPhone maker posted a modest gain, looking to extend recent highs and approaching a $3T market cap -- the first megacap to reach that lofty valuation. Peloton Interactive (NASDAQ:PTON) also grabbed some of the p...

bluebird bio (NASDAQ:BLUE) announces updated results from its Phase 1/2 HGB-206 study of lovotibeglogene autotemcel (lovo-cel) gene therapy for sickle cell disease (SCD). Shares up 9.3% premarket at $9.79. In addition to continued complete resolution of severe vaso-occlusive events ...